6 active not recruiting. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 6 |
Follow Thymoma: new trials by email Literature Review of Thymoma trials Research Report on Thymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma M7824 - Thymic Epithelial Tumor, Recurrent Thymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2020-12-26 | 2026-10-16 |
| Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate - Thymic Carcinoma | Phase 2 | Active not recruiting | Dwight Owen | 9 | 2018-06-19 | 2026-08-06 |
| Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Nivolumab - Thymoma Type B3, Thymic Carcinoma | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 55 | 2018-04-11 | 2026-05-15 |
| A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Avelumab - Thymoma, Thymic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 56 | 2017-04-19 | 2026-10-29 |
| Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide - Thymoma, Thymic Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2009-12-01 | 2026-07-29 |
Carcinoid Tumor (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Gestational Trophoblastic Disease (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Thymic epithelial tumor (1) · Thymus Neoplasms (1) · Thyroid Carcinoma, Anaplastic (1)
Hemic and Lymphatic Diseases (6) · Lymphatic Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Complex and Mixed (6) · Thoracic Neoplasms (6) · Thymus Neoplasms (5) · Adenocarcinoma (1) · Carcinoma (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1)
Cetuximab (1) · Cisplatin (1) · Cyclophosphamide (1) · Doxorubicin (1) · Nivolumab (1) · Sunitinib (1) · avelumab (1) · pembrolizumab (1) · zimberelimab (1)
National Cancer Institute (NCI) (2) · Dwight Owen (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hospices Civils de Lyon (1) · Memorial Sloan Kettering Cancer Center (1)
United States (4) · France (2) · Belgium (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Arun Rajan, M.D. (2) · Dwight Owen, MD (1) · James Huang, MD (1) · Nicolas Girard (1) · Solange Peters (1)
2015 (1)